When Did Ozempic Come Out? A Complete Approval Timeline and What Changed

Ozempic has become one of the most recognizable prescription medications in the world, but its story started long before the name became a household term. The drug’s active ingredient, semaglutide, belongs to a class of medicines known as GLP-1 receptor agonists, which were developed from decades of research into how the body regulates blood sugar, appetite, and metabolism.

So, when did Ozempic come out? The answer depends on what part of its history you mean. Ozempic was first approved by the U.S. Food and Drug Administration (FDA) in December 2017 for adults with type 2 diabetes. Its later association with weight management came from the same semaglutide molecule being developed at a higher dose under the brand name Wegovy.

Understanding that distinction helps explain why the “Ozempic approval date” is sometimes confused with several other important milestones.

From Gila Monster Venom to GLP-1 Medicines

The history of modern GLP-1 medications has a surprisingly unusual beginning: the Gila monster, a venomous lizard found in the southwestern United States.

In the 1990s, researcher John Eng at the Bronx VA Medical Center isolated a peptide called exendin-4 from Gila monster saliva. Researchers discovered that exendin-4 could stimulate insulin release in a way similar to human GLP-1. More importantly, it was far more resistant to enzymatic breakdown.

Human GLP-1 has an extremely short half-life of roughly one to two minutes, while exendin-4 lasts for several hours. That stability made it much more practical as a potential medication.

Synthetic exendin-4 eventually became exenatide, marketed as Byetta. It received FDA approval in April 2005 for type 2 diabetes and initially required twice-daily injections.

The next major step came with liraglutide, marketed as Victoza, which was approved in 2010. Its modified structure allowed it to remain active much longer than naturally occurring GLP-1, making once-daily treatment possible.

Researchers then continued looking for ways to extend GLP-1 activity even further.

How Semaglutide Changed GLP-1 Treatment

Semaglutide was first synthesized in 2008. Its molecular structure was designed to resist breakdown by the DPP-4 enzyme while also binding strongly to albumin in the bloodstream.

The result was a remarkably long half-life of approximately seven days.

That long duration made something important possible: once-weekly dosing.

Between 2012 and 2016, Novo Nordisk studied semaglutide through the SUSTAIN clinical trial program, which included 10 major trials and more than 8,000 participants. The program evaluated semaglutide across different patient populations and helped establish its effectiveness and safety profile.

The FDA approved Ozempic in December 2017 for adults with type 2 diabetes.

The move from twice-daily injections with early GLP-1 medicines to once-weekly treatment represented a major improvement in convenience and helped push GLP-1 therapy into the mainstream.

The GLP-1 Approval Timeline

Ozempic was not the first GLP-1 medicine, and it was certainly not the last. Several important drugs appeared before and after it.

2005–2014: The Early GLP-1 Era

April 2005: Byetta (exenatide) was approved for type 2 diabetes.
January 2010: Victoza (liraglutide) introduced once-daily treatment.
January 2012: Bydureon brought extended-release exenatide to a weekly schedule.
April 2014: Tanzeum (albiglutide) was approved as a weekly treatment but was later withdrawn.
September 2014: Trulicity (dulaglutide) was approved for type 2 diabetes.
December 2014: Saxenda, a higher-dose version of liraglutide, was approved for chronic weight management.

2017–2024: The Semaglutide Era

December 2017: Ozempic (semaglutide) was approved for type 2 diabetes.
September 2019: Rybelsus introduced oral semaglutide for type 2 diabetes.
June 2021: Wegovy, using semaglutide at a higher dose, was approved for chronic weight management.
May 2022: Mounjaro (tirzepatide) was approved for type 2 diabetes.
November 2023: Zepbound, tirzepatide for chronic weight management, was approved.
2024: Wegovy gained an additional cardiovascular-risk-reduction indication for eligible adults with obesity or overweight and cardiovascular disease.

Each stage represented progress in dosing convenience, effectiveness, or the number of conditions for which these medicines could be used.

Why Ozempic Became So Popular

Ozempic's popularity cannot be explained by a single factor.

First, its once-weekly dosing was considerably more convenient than older GLP-1 treatments that required daily or twice-daily injections.

Second, clinical trials demonstrated substantial reductions in blood glucose. In the SUSTAIN program, the 1.0 mg dose produced HbA1c reductions of roughly 1.5% to 1.8% in some study populations.

Weight loss also attracted enormous attention. Although Ozempic was approved for diabetes rather than general weight loss, many patients experienced meaningful reductions in body weight while taking it. That observation helped fuel widespread interest in semaglutide for weight management.

Cardiovascular outcomes added another important dimension. The SUSTAIN-6 trial found that semaglutide reduced major cardiovascular events in certain high-risk patients with type 2 diabetes.

Then came the cultural phenomenon.

Beginning around 2022, celebrity discussions, social media posts, news coverage, and growing public awareness turned GLP-1 medications into a mainstream topic. Demand increased dramatically, contributing to supply shortages affecting Ozempic and Wegovy.

How Ozempic Became Part of the Weight-Loss Conversation

Ozempic itself was approved for type 2 diabetes. However, weight loss seen during diabetes treatment generated substantial interest in using semaglutide for weight management.

Novo Nordisk ultimately developed Wegovy, which contains the same active ingredient but uses a higher maintenance dose.

Wegovy received FDA approval in June 2021 for chronic weight management in adults with obesity or adults who are overweight and have at least one weight-related health condition.

The STEP 1 trial was particularly influential. Participants receiving semaglutide 2.4 mg experienced average weight loss of approximately 14.9% over 68 weeks, compared with about 2.4% with placebo.

That result helped establish semaglutide as one of the most significant developments in modern medical weight management.

Ozempic, Wegovy, and Rybelsus: What's the Difference?

Although Ozempic, Wegovy, and Rybelsus all contain semaglutide, they are not interchangeable products.

Ozempic is a once-weekly injection primarily approved for type 2 diabetes.

Wegovy is also a once-weekly injection, but it uses a higher dose and is approved for chronic weight management, with additional cardiovascular-risk-reduction indications for certain patients.

Rybelsus contains oral semaglutide and is taken daily for type 2 diabetes.

The distinction is therefore not simply about the brand name. Dose, route of administration, approved indication, and clinical circumstances all matter.

For patients, one of the most useful steps is to focus on the specific medication and indication rather than treating “Ozempic” as a generic name for every GLP-1 drug.

What Happened With the GLP-1 Shortage?

The enormous increase in demand created supply problems for semaglutide and other GLP-1 medicines.

During the shortage period, federal regulations allowed certain licensed compounding pharmacies to prepare compounded versions of medications under specific circumstances. This created another segment of the GLP-1 market between 2022 and 2024.

However, compounded medications are not automatically equivalent to FDA-approved branded products. Anyone considering a compounded medication should verify that the pharmacy is properly licensed and understand how the product is sourced, prepared, tested, and labeled.

The regulatory situation has continued to evolve as supply conditions have changed, making it important to check current FDA guidance rather than relying on outdated information.

What Could Come Next?

The semaglutide story is still developing.

Researchers are investigating higher-dose oral semaglutide for obesity, as well as combination and next-generation therapies. CagriSema combines semaglutide with cagrilintide, while retatrutide targets GLP-1, GIP, and glucagon receptors.

Other medicines, including survodutide and the oral GLP-1 drug orforglipron, are also being studied.

These treatments could eventually offer additional choices for people who cannot tolerate existing therapies or who need greater effectiveness. Their ultimate role will depend on clinical results, safety, tolerability, availability, and cost.

The Bottom Line

Ozempic did not suddenly appear as a weight-loss medication. Its history stretches back decades, beginning with research into GLP-1 biology and the surprising discovery of exendin-4 in Gila monster saliva.

The key milestone came in December 2017, when Ozempic was FDA-approved for type 2 diabetes. Later developments—including oral semaglutide, higher-dose Wegovy, cardiovascular research, and growing public interest in weight management—expanded the story far beyond its original diabetes indication.

That is why several dates can appear when researching when Ozempic “came out.” The 2017 approval refers specifically to Ozempic for type 2 diabetes, while the 2021 Wegovy approval marks the major transition of semaglutide into chronic weight management.

For anyone researching these medications, the most useful approach is to look beyond the brand name and check the specific drug, dose, formulation, FDA-approved indication, and date of approval. The GLP-1 field has changed rapidly, and understanding that timeline makes today's treatment landscape much easier to navigate.